Paclitaxel Injection Clinical Trials
9 recruitingDrug
Phase 36Phase 25Phase 11
Showing 1–9 of 9 trials
Recruiting
Phase 2
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd110 enrolled7 locationsNCT07331155
Recruiting
Phase 1Phase 2
A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer
Ovarian Cancer
Nanjing Leads Biolabs Co.,Ltd110 enrolled13 locationsNCT07042802
Recruiting
Phase 2
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Advanced Solid Tumour
Nanjing Leads Biolabs Co.,Ltd230 enrolled24 locationsNCT06783647
Recruiting
Phase 3
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Advanced Cervical Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd720 enrolled1 locationNCT07168200
Recruiting
Phase 3
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Shanghai Hengrui Pharmaceutical Co., Ltd.402 enrolled1 locationNCT06738251
Recruiting
Phase 3
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.300 enrolled2 locationsNCT06828354
Recruiting
Phase 2Phase 3
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Gastric CancerGastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.90 enrolled12 locationsNCT06221748
Recruiting
Phase 2Phase 3
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Stomach Cancer
Shanghai JMT-Bio Inc.286 enrolled1 locationNCT05427383
Recruiting
Phase 3
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
Advanced or Metastatic Urothelium Cancer
Shanghai Miracogen Inc.290 enrolled1 locationNCT05754853